Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moonward tommorrow thanks shorts for the rocket this week!.!.!.!
This is pointed straight up! After hours! Wait tell the bears cover or some may get a margin call. Looking forward to getting into the $180 channel soon.
Hey Uber, did you hear TSLA robotaxi is coming. 8/8/24? Sorry this is a Short notice if you know what I mean..
That was a perfect call!
SEC should probe Reuters. Can't believe they can manipulate the market like this.
That’s a good tell, someone needed to close out some big shorts.
Over $20 with TRUMP winning republican Super Tuesday states.. PHUN going to be fun.! This will be a buy buy buy day today:)
Mmmmm interesting, and yes I think Elon announces some job cuts this week. If that happens this will be above $200 next week.! Heads up we going up.
This is amazing stuff. Elon creates technology that changes lives.
"The first human received an implant from Neuralink yesterday and is recovering well," Musk said on his X social network. The initial results are showing the implant, which Musk said is named Telepathy, is registering spikes of brain cell activity.
Over .86 now! — Next stop $2..
I think that’s true, this could easily go over $10 after people find out.
It’s hard to see a good company when the price goes into the dumps.. I’d say it’s a very good time to buy this money maker.! .61 are you kidding me:) just loaded more at .61. Thanks very much!
Woohoo nice to see TTOO getting legs. Next stop over .25!
Will turn back down at 269 to finish off The golden shower back under 265
If this can get over .26 this could easily run over .70 fast. Once the shorts realize they are losing .26 this will explode upward quickly maybe even back to $1 next week
+++Adding for gap and run over .30 tomorrow
This is going to get over .30 this really should be over .50!
Did you see the 1st quarter highlights..!?
The fiscal quarter highlights include:
Revenue of approximately $59.0 million
Fifth Consecutive Record Revenue Quarter (based on quarter over quarter)
Revenue increase of 276% over the comparative prior year period
Gross Profit of $8.8 million
Adjusted EBITDA of approximately $1.5 million
Strong Revenue growth in Performance Solutions within Home Services and Professional Services Sectors
Fridays leg going back under $230
I’m not sure about $100, but I can see this going back below $200 this week with Meta lawsuits being paid out..
This company is going places, I bought some more shares at these great prices today… going back at $1.50 quickly..
Nice seeing after hour action today was nice, hopefully some big news on the way, and let’s clear them shorts out! Id like to see $2+
I loaded under $160, think we go over 170+ within a week. IMHO
Aww great news! This will get back to $5+ tomorrow for sure
This could get some nice legs over 6+, next week could be very interesting..
Pamela, please include me..
Thanks
This is gonna be bad for Ubers stock, I can see this going under $50 easy and maybe back down under $30 within months.. Most of the states if not the whole USA will also probably be doing something like this within the year...
On Tuesday, Uber said it would reclassify more than 70,000 drivers in Britain as workers who will receive a minimum wage, vacation pay and access to a pension plan. The decision, Uber said, is the first time the company has agreed to classify its drivers in this way,
I’ve already been adding more at $8, if it hits $7 I’ll buy another 1000. This is going higher, only a matter of time ....
Yeah the 10q looks great with good growth... This should be a nice lil breakout on Tuesday..!
Yeah looks to me this is about to break over 2.25 and start to run much faster... don’t be short:)
It really sucks that this market is so hot right now and SOLI is stuck in the grey market.. I know everyone is hoping SOLI solves its issues quickly because the market is bound to cool off sometime... TIME is MONEY, and they should have been taking advantage of all this.! I know if they were trading normal I’d probably have 30K+ personally invested here.. Only a matter of time I keep saying, but feeling the cabin fever is really kicking me now, been here for 2 years.. Atleast my capital gains will be considered long term now.!.! Lol
Ok my rant is over.. good luck to us all...!
DailyX
This is going over $10 this week, don’t be short...
Glad I sold a good amount at $3, reloading at 2.20 now, for more fun tomorrow...
Looking for alittle breakout over 5.60!
Someone got 18,000 shares at .05!? That’s one lucky person! Lol
Weeeee BNGO, open at 2+ tomorrow!
.75. Really nice;)
Looking good after hours today.. let’s get back over $1
Hopefully we get some legs with this news:) after hours looked good!
https://finance.yahoo.com/news/multi-center-evaluation-bionano-optical-231000096.html
Analysts’ Opinion of BNGO
Many brokerage firms have already submitted their reports for BNGO stocks, with Ladenburg Thalmann repeating the rating for BNGO by listing it as a “Buy.” The predicted price for BNGO in the upcoming period, according to Ladenburg Thalmann is $1.25 based on the research report published on September 24th of the current year 2020.
Oppenheimer, on the other hand, stated in their research note that they expect to see BNGO reach a price target of $1.50. The rating they have provided for BNGO stocks is “Outperform” according to the report published on April 08th, 2020.
Largest Study To-Date Focused on Undiagnosed Genetic Disease Patients Reveals That Bionano’s Optical Genome Mapping Technology Can Diagnose Significantly More Patients Than Standard of Care Methods Alone
Publication from UCSF shows Bionano’s optical genome mapping technology can detect pathogenic variants missed by whole exome sequencing and by chromosomal microarray in patients with rare genetic disorders and may contribute to more patients receiving definitive molecular diagnoses
November 05, 2020 08:00 ET | Source: Bionano Genomics
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study led by scientists and clinicians from the Institute for Human Genetics and the Benioff Children’s Hospital at the University of California, San Francisco (UCSF) that evaluated the ability of Bionano’s optical genome mapping technology and another genome analysis method to diagnose children with genetic conditions who previously went undiagnosed by the standard of care methods alone. Of the 50 children in the study, the optical genome mapping results were sufficient to definitively diagnose 6 patients (or 12%) and, for another 10 patients (or 20%), the Bionano data revealed candidate pathogenic variants. Upon further analysis, it is expected that an additional 3 patients could be diagnosed with the Bionano data, bringing the total of definitively diagnosed patients to 9 (or 18%).
Erik Holmlin, Ph.D., CEO of Bionano Genomics commented, “Increasing the number of patients who receive a definitive molecular diagnosis is the driving force behind much of the development of new diagnostic technologies. Every major change in medical guidelines connected to introducing novel methods has been driven by the ability of new methods to diagnose more patients than the previously existing standard of care. This study by the UCSF team shows that Bionano’s optical genome mapping can potentially bring another such leap to the clinic by diagnosing many more patients than what existing chromosomal microarray (CMA) and whole exome sequencing (WES) can. Several studies released this year have shown that Saphyr can detect all clinically relevant variants identified by karyotyping, microarray and FISH in both leukemias and genetic disease cases. This UCSF study now shows in the largest cohort analyzed to date that Bionano’s optical genome mapping diagnoses more patients than the traditional methods. We believe the increase in diagnosis over conventional methods can be a significant factor in Saphyr gaining widespread adoption as a clinical tool for genetic disease diagnosis and next-generation cytogenomics.”
As described in the publication, the UCSF team performed full genome analysis by combining optical genome mapping with Bionano technology and linked-read sequencing on 50 undiagnosed patients with a variety of rare genetic diseases and their parents to determine if this full genome analysis method could help solve cases that had not been diagnosed with previous testing. Of the 50 cases, 42 were previously analyzed by CMA, the first tier medical test for genetic disease cases, and 23 had previously been analyzed with commercial trio whole exome sequencing, and no pathogenic or likely pathogenic variants were identified by these methods.
Bionano’s optical genome mapping technology identified a number of pathogenic variants unidentified by CMA and undetectable by WES, including duplications and deletions that were too small to be identified by CMA, or occurred in regions of the genome not typically covered by CMA or WES. Of the additional 7 patients with variations considered to be candidates for pathogenic variants, the findings included deletions, duplications, and inversions. Before concluding that these variants are sufficient to diagnose the patients, further analysis is required since these variants had not previously been reported in patients with similar disease.